

Press Release: Financial Result for Half Yearly & Year Ended March 31, 2026

Financial Results Highlights:

₹ lakhs unless otherwise mentioned	H2 FY26	H2 FY25	YoY change (%)	FY26	FY25	YoY change (%)
Revenue from operations	8,006.9	5,679.4	41.0%	14,683.4	10,485.4	40.0%
EBITDA	1,519.9	1,147.3	32.5%	2,986.1	2,057.1	45.2%
EBITDA Margin	19.0%	20.2%	-122 bps	20.3%	19.6%	72 bps
PAT	1,054.6	765.0	37.9%	2,054.1	1,331.4	54.3%
PAT Margin	13.2%	13.5%	-30 bps	14.0%	12.7%	129 bps
EPS (₹)	4.6	4.2	8.3%	9.4	7.3	27.9%

H2 FY26 & FY26 Financial Performance Highlights:

- Revenue from operations stood at ₹8,006.90 lakhs for H2 FY26, registering 41% year-on-year growth, bringing full-year FY26 total revenues to ₹14,683.36 lakhs, up 40.0% year-on-year.
- EBITDA stood at ₹1,519.92 lakhs for H2 FY26, up 32.5% year-on-year, with EBITDA margin at 19.0%. For full-year FY26, EBITDA reached ₹2,986.13 lakhs, up 45.2% year-on-year, with EBITDA margin at 20.3%.
- Net Profit (PAT) stood at ₹1,054.59 lakhs for H2 FY26, up 37.9% year-on-year, with net profit margin at 13.2%. For full-year FY26, Net Profit reached ₹2,054.13 lakhs, up 54.3% year-on-year, with net profit margin at 14.0%.
- Earnings Per Share (EPS) stood at ₹4.56 for H2 FY26, up 8.3% year-on-year. For full-year FY26, EPS reached ₹9.35, up 27.9% year-on-year, reflecting strong per-share value creation.

Segment-Wise performance

- Nutraceuticals segment continued to remain the dominant revenue contributor, accounting for ~90% of FY26 revenue, supported by strong growth of 40.3% YoY to ₹13,190.58 lakhs.
- Ayurvedic segment witnessed strong momentum, growing 88.9% YoY to ₹611.77 lakhs in FY26, reflecting increasing traction in herbal and wellness-focused formulations.
- Cosmetics segment recorded steady growth, with FY26 revenue increasing 15.8% YoY to ₹742.42 lakhs, supported by expanding customer engagements.
- Revenue mix remained largely stable during FY26, with nutraceuticals continuing to anchor the portfolio while other segments gradually scaling contribution.

Other Key Operational Highlights:

- Secured a 5-year FSSAI license for the new rented facility to manufacture health and dietary supplements, strengthening regulatory compliance and market positioning.
- Capacity expansion - Invested ₹60 lakhs to boost tablet capacity from 20,000 to 30,000-35,000 bottles per day, supporting growing market demand.
- Introduced the Quick Snap Machine to enhance operational efficiency and production capabilities.
- Received compliance approval with the Good Manufacturing Practices (GMP), enabling Influx to expand to Tanzania market.
- Incorporated Olahey Wellness Private Limited with a ₹1,00,000 cash investment to manufacture Ready-to-Drink wellness beverages, expanding product portfolio.

Management Commentary by Dr. Munir Chandniwala, Chairman & MD:



In FY26, **Influx Healthtech** delivered strong growth driven by strategic expansion, innovation, and market diversification. In FY26, the company reported approximately **40% year-on-year revenue growth**, supported by robust demand across its core **nutraceutical and pharmaceutical CDMO segments**. During the year, the company strengthened its innovation capabilities with the development of **Quick Snap™ Technology** and **MMTC Technology**, enhancing its advanced delivery and formulation offerings. The incorporation of **Olahey Wellness Private Limited** further expanded the company's presence within the wellness ecosystem. On the international front,

Influx received approval for the **Tanzania market**, strengthening its African footprint alongside Nigeria, while continuing efforts toward registrations in additional export markets. The company is also progressing plans to establish manufacturing operations in the **UAE through RAKEZ, Ras Al Khaimah**, supporting its global expansion strategy. Further, the company's capex program remains on track, with **IPO-funded machinery installations** expected to enhance production capacity across multiple formats. Looking ahead, Influx also plans to expand into the **pet nutrition and wellness segment** through a dedicated subsidiary.

Supported by capacity expansion, innovation, and international growth initiatives, the company remains confident of sustaining strong growth momentum and creating long-term stakeholder value.

About Influx Healthtech Limited:

Influx Healthtech Limited is a CDMO founded in 2020 by Dr. Munir Abdul Ganeer Chandniwala, specializing in nutraceuticals, cosmetics, pet care, and home care products. The Company provides end-to-end solutions including product development, manufacturing, regulatory support, and commercialization, serving a global clientele across 36 countries with a portfolio of over 3,400 products.

The Company operates manufacturing facilities in Palghar, Maharashtra, backed by certifications including FSSAI, GMP, HACCP, Halal, ISO, NSF, and FDA registration for food products. Driven by innovation, quality, and client-centric solutions, Influx was listed on the NSE Emerge platform in June 2025, raising ₹4,474.75 lakhs (net of IPO expenses) to support capacity expansion and future growth.

For further information, please contact



Company
Influx Healthtech Limited

info@influxhealthtech.com
91 - 80803 33319



Investor relations consultants
Capital Bridge Advisory Service Private Limited

Raj Shah, CFA
Raj@capbridge.in
91 - 99259 11296

Hrishit Jhaveri, CFA
Hrishit@capbridge.in
91 - 90999 94345